Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

被引：20

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Derkach, Andriy ^{[2
]}

Gowda, Lohith ^{[1
]}

Menghrajani, Kamal ^{[3
,4
]}

DeWolf, Susan ^{[3
]}

Ruiz, Josel D. ^{[5
]}

Ponce, Doris M. ^{[4
,5
]}

Shaffer, Brian C. ^{[4
,5
]}

Tamari, Roni ^{[4
,5
]}

Young, James W. ^{[4
,5
,6
]}

Jakubowski, Ann A. ^{[4
,5
]}

Gyurkocza, Boglarka ^{[4
,5
]}

Chan, Alexander ^{[7
]}

Xiao, Wenbin ^{[7
]}

Glass, Jacob ^{[3
,4
]}

King, Amber C. ^{[8
]}

Cai, Sheng F. ^{[3
,4
]}

Daniyan, Anthony ^{[3
,4
]}

Famulare, Christopher ^{[3
]}

Cuello, Bernadette M. ^{[3
]}

Podoltsev, Nikolai A. ^{[1
]}

Roshal, Mikhail ^{[7
]}

Giralt, Sergio ^{[4
,5
]}

Perales, Miguel-Angel ^{[4
,5
]}

Seropian, Stuart ^{[1
]}

Cho, Christina ^{[4
,5
]}

Zeidan, Amer M. ^{[1
]}

Prebet, Thomas ^{[1
]}

Stein, Eytan M. ^{[3
,4
]}

Tallman, Martin S. ^{[3
,4
]}

Goldberg, Aaron D. ^{[3
,4
]}

Stahl, Maximilian ^{[3
,4
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA

[6] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pharm, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 14期

基金：

美国国家卫生研究院;

关键词：

Acute myeloid leukemia; AML; MDS; venetoclax; transplant; RELAPSE;

D O I：

10.1080/10428194.2021.1966788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.

引用

页码：3394 / 3401

页数：8

共 50 条

[21] Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Brauer, Dominic
Bischof, Lara
Ussmann, Jule
Backhaus, Donata
Franke, Georg-Nikolaus
Vucinic, Vladan
Herling, Marco
Merz, Maximilian
Braunert, Leanthe
Hammerschmidt, Doreen
Kuehnemund, Alexander
Weigert, Anne
Metzeler, Klaus H.
Platzbecker, Uwe
Jentzsch, Madlen
Schwind, Sebastian
BLOOD, 2022, 140 : 4808 - 4809
[22] Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS
Cao, Yigeng
Guo, Wenwen
Zhai, Weihua
Wei, Jialin
Ma, Qiaoling
Yang, Donglin
Pang, AiMing
Han, Mingzhe
Jiang, Erlie
BLOOD, 2023, 142
[23] Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML
Bjorklund, Andreas T.
Carlsten, Mattias
Sohlberg, Ebba
Clancy, Trevor
Liu, Lisa
Karimi, Mohsen
Cooley, Sarah
Miller, Jeffrey S.
Watz, Emma
Wahlin, Bjorn Engelbrekt
Palma, Marzia
Hansson, Lotta
Ljungman, Per
Hellstrom-Lindberg, Eva
Ljunggren, Hans-Gustaf
Malmberg, Karl-Johan
BLOOD, 2017, 130
[24] Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation
Heuser, Michael
Koenecke, Christian
Gabdoulline, Razif
Loeffeld, Patrick
Dobbernack, Vera
Panagiota, Victoria
Klesse, Sabrina
Stadler, Michael
Krauter, Juergen
Dammann, Elke
Wichmann, Martin
Shahswar, Rabia
Bhuju, Sabin
Geffers, Robert
Schlegelberger, Brigitte
Goehring, Gudrun
Kleine, Moritz
Brauns, Wiebke
Platzbecker, Uwe
Thiede, Christian
Schroeder, Thomas
Kobbe, Guido
Ganser, Arnold
Kroeger, Nicolaus
Thol, Felicitas
BLOOD, 2015, 126 (23)
[25] Impact of prior solid tumor on outcomes of allogeneic hematopoietic stem cell transplantation for AML or MDS.
Albittar, Aya
Portuguese, Andrew Jay
Gooley, Ted
Deeg, H. Joachim
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
Ohm, AC
Hast, R
Bernell, P
Celsing, F
Dahl, IM
Dybedal, I
Lindberg, G
Linder, O
Löfvenberg, E
Nilsson-Ehle, H
Samuelsson, J
Tangen, J
Turesson, I
Wallvik, J
Winquist, I
Öberg, G
Björkholm, M
Hellström-Lindberg, E
BLOOD, 2000, 96 (11) : 148A - 148A
[27] Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Lachowiez, Curtis A.
Ravikumar, Vishvaas I.
Othman, Jad
O'Nions, Jenny
Peters, Daniel T.
Mcmahon, Christine
Swords, Ronan
Cook, Rachel
Saultz, Jennifer N.
Tyner, Jeffrey W.
Dillon, Richard
Zeidner, Joshua F.
Pollyea, Daniel A.
BLOOD, 2024, 144 (26) : 2788 - 2792
[28] T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
Satty, Alexandra M.
Klein, Elizabeth
Mauguen, Audrey
Kunvarjee, Binni
Boelens, Jaap Jan
Cancio, Maria
Curran, Kevin J.
Kernan, Nancy A.
Prockop, Susan E.
Scaradavou, Andromachi
Spitzer, Barbara
Tamari, Roni
Ruggiero, Julianne
Torok-Castanza, Joanne
Mehta, Parinda A.
O'Reilly, Richard J.
Boulad, Farid
BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 23 - 33
[29] T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML
Alexandra M. Satty
Elizabeth Klein
Audrey Mauguen
Binni Kunvarjee
Jaap Jan Boelens
Maria Cancio
Kevin J. Curran
Nancy A. Kernan
Susan E. Prockop
Andromachi Scaradavou
Barbara Spitzer
Roni Tamari
Julianne Ruggiero
Joanne Torok-Castanza
Parinda A. Mehta
Richard J. O’Reilly
Farid Boulad
Bone Marrow Transplantation, 2024, 59 : 23 - 33
[30] T cell depleted (TCD) allogeneic hematopoietic stem cell transplant for older patients with advanced MDS and AML evolved from MDS
Tamari, R.
Chung, S.
Devlin, S.
Jakubowski, A.
Papadopoulos, E.
Perales, M. A.
Ponce, D.
Goldberg, J.
Barker, J.
Sauter, C.
Koehne, G.
Young, J.
Giralt, S.
Castro-Malaspina, H.
LEUKEMIA RESEARCH, 2013, 37 : S122 - S122

← 1 2 3 4 5 →